BeyondSpring Inc. (BYSI) Gets FDA Fast Track; Sells China Sub for DUBLIN-4 Support
BeyondSpring received FDA Fast Track for plinabulin plus docetaxel in post-ICI non-squamous NSCLC and agreed to sell its Chinese subsidiary to Biolin, which will fund China enrollment for the global Phase 3 DUBLIN-4 trial.Material DetailsContext by AI AnalystThis is mid-stage progress in BeyondSpri…